Your browser doesn't support javascript.
loading
Ligand-Based and Structure-Based Virtual Screening of New Sodium Glucose Cotransporter Type 2 Inhibitors.
Estrada, Ana Karen; Mendez-Alvarez, Domingo; Juarez-Saldivar, Alfredo; Lara-Ramirez, Edgar E; Martinez-Vazquez, Ana Veronica; Villalobos-Rocha, Juan Carlos; Palos, Isidro; Ortiz-Perez, Eyra; Rivera, Gildardo.
Afiliação
  • Estrada AK; Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, 88710 Reynosa, Mexico.
  • Mendez-Alvarez D; Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, 88710 Reynosa, Mexico.
  • Juarez-Saldivar A; Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, 88710 Reynosa, Mexico.
  • Lara-Ramirez EE; Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, 88710 Reynosa, Mexico.
  • Martinez-Vazquez AV; Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, 88710 Reynosa, Mexico.
  • Villalobos-Rocha JC; Departamento de Microbiologia, Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, 11340 Ciudad de Mexico, Mexico.
  • Palos I; Unidad Academica Multidisciplinaria Reynosa-Rodhe, Universidad Autonoma de Tamaulipas, 88779 Reynosa, Mexico.
  • Ortiz-Perez E; Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, 88710 Reynosa, Mexico.
  • Rivera G; Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, 88710 Reynosa, Mexico.
Med Chem ; 19(10): 1049-1060, 2023.
Article em En | MEDLINE | ID: mdl-37534786
ABSTRACT

BACKGROUND:

Diabetes mellitus is a metabolic disease that causes multiple complications and common comorbidities, which decreases the quality of life for people affected by the disease. Sodium glucose cotransporter type 2 (SGLT2) participates in the reabsorption of 90% of glucose in the kidneys; therefore, it is an attractive drug target for controlling blood glucose levels.

OBJECTIVE:

The aim in this work was to obtain new potential SGLT2 inhibitors.

METHODS:

A ligand-based virtual screening (LBVS) from the ZINC15, PubChem and ChemSpider databases using the maximum common substructure (MCS) scaffold was performed.

RESULT:

A total of 341 compounds were obtained and analyzed by molecular docking on the active site of SGLT2. Subsequently, 15 compounds were selected for molecular dynamics (MD) simulation analysis. The compounds derived of spiroketal Sa1, Sa4, and Sa9 (≤ 3.5 Å) in complex with the receptor SGLT2 showed good stability during 120 ns of MD.

CONCLUSION:

These compounds are proposed as potential SGLT2 inhibitors.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article